Bioventus Inc is a medical devices business based in the US. Bioventus shares (BVS) are listed on the NASDAQ and all prices are listed in US Dollars. Bioventus employs 900 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $14.09 |
|---|---|
| 52-week range | $10.74 - $19.94 |
| 50-day moving average | $14.15 |
| 200-day moving average | $15.21 |
| Wall St. target price | $21.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.48 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $14.09 from 2022-01-21
| 1 week (2022-01-14) | -3.82% |
|---|---|
| 1 month (2021-12-23) | 0.79% |
| 3 months (2021-10-22) | -7.79% |
| 6 months (2021-07-23) | -15.48% |
| 1 year (2021-01-19) | N/A |
|---|---|
| 2 years (2020-01-19) | N/A |
| 3 years (2019-01-19) | N/A |
| 5 years (2017-01-19) | N/A |
Valuing Bioventus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioventus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bioventus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6321. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bioventus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Bioventus's PEG ratio in relation to those of similar companies.
Bioventus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $59.6 million.
The EBITDA is a measure of a Bioventus's overall financial performance and is widely used to measure a its profitability.
To put Bioventus's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $399.1 million |
|---|---|
| Operating margin TTM | 9.28% |
| Gross profit TTM | $233.5 million |
| Return on assets TTM | 4.08% |
| Return on equity TTM | 7.31% |
| Profit margin | 5.64% |
| Book value | $3.71 |
| Market capitalisation | $870.8 million |
TTM: trailing 12 months
We're not expecting Bioventus to pay a dividend over the next 12 months.
You may also wish to consider:
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Steps to owning and managing CORZ, with 24-hour and historical pricing before you buy.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.